Clinical Trial: A Study to Assess the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus Infection

U.S., Aug. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07762027) titled 'A Study to Assess the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus Infection' on Aug. 05.

Brief Summary: This study is designed to assess safety, pharmacokinetics, and efficacy ABI-6250 in participants with Chronic Hepatitis D Virus Infection.

Study Start Date: Oct., 2026

Study Type: INTERVENTIONAL

Condition: Chronic Hepatitis D Infection

Intervention: DRUG: ABI-6250

Once daily tablet dosing for 48 weeks starting at Day 1 visit

DRUG: ABI-6250

Once daily tablet dosing for 48 weeks, starting at Week 16 visit

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Assembly Bioscie...